Cipla is eyeing to continue capital expenditure on automation for next three years. The company has started its investment journey on the automation front two years ago and has already been recognised for its work by multiple bodies. The World Economic Forum (WEF) has recognised one of its four manufacturing units as a 'lighthouse' project for being replicated across the world. The company will be implementing the same across all of its 42 plants.
The journey on automation has its roots in a decision Cipla took in 2020, where it started with reimagining technology and making it more cost-effective. The company’s main aim at the organisation level is to produce high quality products which comply with sustainability goals, which are affordable and leave the planet safer.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1877.40 |
| Dr. Reddys Labs. | 1358.50 |
| Cipla | 1443.80 |
| Zydus Lifesciences | 1105.05 |
| Lupin | 2371.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: